Eton Pharmaceutcials
ETON
Market cap $383M

14.30 USD

-0.21

1.45%

At close Jun 13, 4:00 PM EDT

After hours

14.48

+0.18

1.26%

1 day

-1.45%

5 days

-16.76%

1 month

-16.23%

3 months

-2.05%

6 months

15.79%

Year to date

-0.07%

1 year

293.94%

5 years

160.00%

10 years

128.80%

About: Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Employees: 31

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

136% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 11

87% more call options, than puts

Call options by funds: $891K | Put options by funds: $476K

32% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 22

21% more funds holding

Funds holding: 70 [Q4 2024] → 85 (+15) [Q1 2025]

3.35% more ownership

Funds ownership: 49.31% [Q4 2024] → 52.66% (+3.35%) [Q1 2025]

5% more capital invested

Capital invested by funds: $175M [Q4 2024] → $183M (+$8.36M) [Q1 2025]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$26

82%

upside

Avg. target

$30

107%

upside

High target

$35

145%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Swayampakula Ramakanth	145%upside $35	Buy Maintained	29 May 2025
B. Riley Securities Madison El-Saadi	82%upside $26	Buy Reiterated	16 May 2025
Craig-Hallum Chase Knickerbocker	96%upside $28	Buy Maintained	14 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about ETON published over the past 30 days

Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside

Eton Pharmaceuticals is experiencing explosive rare-disease revenue growth, with a 117% YoY increase and a robust pipeline fueling future expansion. Despite a 400% share price surge, ETON remains attractively valued versus peers, offering high growth potential for risk-tolerant investors. Operational leverage is improving, and near-term catalysts—product launches, label expansions, and M&A—could drive further upside as profitability approaches.

Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside

Zacks Investment Research

Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why

Eton Pharmaceuticals (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why

Zacks Investment Research

Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why

Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.'s ETON new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric patients five years of age and older with adrenocortical insufficiency.

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd • Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

Eton Pharmaceuticals Set To Dominate Orphan Drug Niche

Giant pharma companies are not the right owners of ultra-rare disease orphan drugs. The associated revenue streams are simply too small. ETON can acquire and develop these drugs, better serving patients and investors. The model is already working well. ETON is able to execute on straightforward product improvements, and has the focus to educate specialist doctors on the need for these rare drugs.

Eton Pharmaceuticals Set To Dominate Orphan Drug Niche

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, and David Krempa, Chief Business Officer, will participate in two upcoming investor conferences as follows:

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Madison Elsaadi - B. Riley Swayampakula Ramakanth - H.C.

Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.03 per share a year ago.

Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

DEER PARK, Ill., May 13, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended March 31, 2025.

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™